Emily Marion Gibson, PA-C | |
815 Freeport Rd, Pittsburgh, PA 15215-3301 | |
(412) 784-5374 | |
Not Available |
Full Name | Emily Marion Gibson |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 815 Freeport Rd, Pittsburgh, Pennsylvania |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093181463 | NPI | - | NPPES |
1031098860001 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | MA057964 (Pennsylvania) | Secondary |
363AS0400X | Physician Assistant - Surgical | (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Emily Marion Gibson, PA-C 815 Freeport Rd, Pittsburgh, PA 15215-3301 Ph: (412) 784-5374 | Emily Marion Gibson, PA-C 815 Freeport Rd, Pittsburgh, PA 15215-3301 Ph: (412) 784-5374 |
News Archive
Portland State biologist Ken Stedman has received a $540,000 grant from NASA to study the evolution of viruses, which may shed light on how viruses form, adapt and infect hosts.
Ethicon Endo-Surgery, Inc. today announced the launch of EESadvancements.com, a new Web site designed to give surgeons advanced access to some of the company's newest surgical technology innovations before they reach full-scale release in the marketplace. The site also offers a collaborative environment where healthcare partners including surgeons, materials managers and OR Directors can share ideas on advancing the surgical continuum beyond minimally invasive procedures.
If you suffer from COPD, staying cool this summer may provide much more significant benefits than simply feeling more comfortable. A study from researchers at Johns Hopkins University says it may also keep you healthier.
Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.
› Verified 8 days ago